References
- Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
- Melnyk A, Rodriguez A, Pugh W C, Cabannillas F. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89: 4514–4520
- Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92: 76–82
- Evens A M, Gartenhaus R B. Treatment of T-cell non-Hodgkin's lymphoma. Curr Treat Options Oncol 2004; 5: 289–303
- Lundin J, Osterborg A. Therapy for mycosis fungoides. Curr Treat Options Oncol 2004; 5: 203–214
- Carson D A, Kaye J, Matsumoto S, Seegmiller J E, Thompson L. Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci USA 1979; 76: 2430–2433
- Shewach D S, Daddona P E, Ashcraft E, Mitchell B S. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res 1985; 45: 1008–1014
- Berg S L, Blaney S M, Devidas M, Lampkin T A, Murgo A, Bernstein M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 2005; 23: 3376–3382
- Kurtzberg J, Ernst T J, Keating M J, Gandhi V, Hodge J P, Kisor D F, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005; 23: 3396–3403
- Gandhi V, Plunkett W, Rodriguez C O, Jr, Nowak B J, Du M, Ayres M, et al. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol 1998; 16: 3607–3615